We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medical Product Stocks' Earnings on Aug 8: NVRO, ICUI & More
Read MoreHide Full Article
The Q2 earnings season is on its last leg with the results of 414 S&P members already out. At last a sigh of relief for the investors -- despite all the idiosyncratic notions of the world market that shrouded the projections earlier in the season -- the results so far portrayed a better picture compared to the last two quarters. With a few earnings reports yet to be announced, this season has more or less confirmed an improving trend.
As per the latest ‘Earnings Outlook’ report, this Q2, despite all its positives will still be represented as the fifth straight quarter of an earnings decline for the S&P 500 index. The scorecard has so far exhibited a 4.5% year-over-year decline in the index’ Q2 earnings on a 1% lower revenues.
Medical, one of the 16 broader Zacks sectors, has been a standout sector exhibiting a promising performance so far. Earnings growth rate stood at 6.3% year over year on account of a 9.8% rise in revenues. For the remainder of the season, earnings are expected to rise 4.4%, driven by an impressive top-line growth expectation of 7.7% in this sector.
What’s in Store for the Med-Product Space?
Medical Product, a specialized sub-sector within the broader Medical sector, is showing a lot of potential as of now. This is impressive given the severe economic instability, fierce competition, and increasing cost related hazards leading to regulatory complexities. The success of the Medical Product industry comes on the back of successful execution of some top strategic priorities, which include R&D and product development; strategic M&A and alliances along with a focus on emerging market expansion.
Let’s take a look at the major Medical Product stocks slated to release their quarterly reports on Aug 8:
Headquartered in Redwood City, CA, Nevro is a global medical product company that develops innovative products for patients suffering from debilitating chronic pain. Nevro is scheduled to report second-quarter 2016 numbers on Aug 8. However, our proven model does not conclusively show that Nevro is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as Nevro currently carries a Zacks Rank #3 and has an earnings ESP of 0.00%. However, we note that Nevro’s trailing 12-month earnings surprise is 19.25%.
This medical device provider catering to infusion therapy, oncology, and critical care applications worldwide is scheduled to report second-quarter 2016 earnings on Aug 8. While a favorable Zacks Rank #3 increases the predictive power of the ESP, a 0.00% ESP makes a surprise prediction difficult. We also note in the last reported quarter, the company registered an earnings beat of 22.22%. The trailing 12-month average surprise came in at a positive 10.15%.
This medical technology company develops and markets non-invasive products for the selective reduction of fat. It carries a Zacks Rank #4 (Sell) and is slated to release its second-quarter 2016 financial numbers on Aug 8. ZELTIQ has a negative Earnings ESP of 114.29%. That is because the Most Accurate estimate stands at a loss of 15 cents while the Zacks Consensus Estimate is pegged at a loss of 7 cents.
However, last quarter, the company posted a positive earnings surprise of 10.71%. Additionally, ZELTIQ’s earnings surpassed the Zacks Consensus Estimate in three of the past four quarters, with an average beat of 71.73%.
This U.S.-based in vitro diagnostics company provides solutions for the diagnosis of serious infections. Accelerate Diagnostics is expected to report second-quarter 2016 earnings on Aug 8. We cannot predict an earnings beat for the company as it has an Earnings ESP of 0.00% and a Zacks Rank #4. We also note in the last reported quarter, the company registered an earnings miss of 11.54%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Medical Product Stocks' Earnings on Aug 8: NVRO, ICUI & More
The Q2 earnings season is on its last leg with the results of 414 S&P members already out. At last a sigh of relief for the investors -- despite all the idiosyncratic notions of the world market that shrouded the projections earlier in the season -- the results so far portrayed a better picture compared to the last two quarters. With a few earnings reports yet to be announced, this season has more or less confirmed an improving trend.
As per the latest ‘Earnings Outlook’ report, this Q2, despite all its positives will still be represented as the fifth straight quarter of an earnings decline for the S&P 500 index. The scorecard has so far exhibited a 4.5% year-over-year decline in the index’ Q2 earnings on a 1% lower revenues.
Medical, one of the 16 broader Zacks sectors, has been a standout sector exhibiting a promising performance so far. Earnings growth rate stood at 6.3% year over year on account of a 9.8% rise in revenues. For the remainder of the season, earnings are expected to rise 4.4%, driven by an impressive top-line growth expectation of 7.7% in this sector.
What’s in Store for the Med-Product Space?
Medical Product, a specialized sub-sector within the broader Medical sector, is showing a lot of potential as of now. This is impressive given the severe economic instability, fierce competition, and increasing cost related hazards leading to regulatory complexities. The success of the Medical Product industry comes on the back of successful execution of some top strategic priorities, which include R&D and product development; strategic M&A and alliances along with a focus on emerging market expansion.
Let’s take a look at the major Medical Product stocks slated to release their quarterly reports on Aug 8:
Nevro Corp. (NVRO - Free Report)
Headquartered in Redwood City, CA, Nevro is a global medical product company that develops innovative products for patients suffering from debilitating chronic pain. Nevro is scheduled to report second-quarter 2016 numbers on Aug 8. However, our proven model does not conclusively show that Nevro is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as Nevro currently carries a Zacks Rank #3 and has an earnings ESP of 0.00%. However, we note that Nevro’s trailing 12-month earnings surprise is 19.25%.
NEVRO CORP Price and EPS Surprise
NEVRO CORP Price and EPS Surprise | NEVRO CORP Quote
ICU Medical, Inc. (ICUI - Free Report)
This medical device provider catering to infusion therapy, oncology, and critical care applications worldwide is scheduled to report second-quarter 2016 earnings on Aug 8. While a favorable Zacks Rank #3 increases the predictive power of the ESP, a 0.00% ESP makes a surprise prediction difficult. We also note in the last reported quarter, the company registered an earnings beat of 22.22%. The trailing 12-month average surprise came in at a positive 10.15%.
ICU MEDICAL INC Price and EPS Surprise
ICU MEDICAL INC Price and EPS Surprise | ICU MEDICAL INC Quote
ZELTIQ Aesthetics, Inc.
This medical technology company develops and markets non-invasive products for the selective reduction of fat. It carries a Zacks Rank #4 (Sell) and is slated to release its second-quarter 2016 financial numbers on Aug 8. ZELTIQ has a negative Earnings ESP of 114.29%. That is because the Most Accurate estimate stands at a loss of 15 cents while the Zacks Consensus Estimate is pegged at a loss of 7 cents.
However, last quarter, the company posted a positive earnings surprise of 10.71%. Additionally, ZELTIQ’s earnings surpassed the Zacks Consensus Estimate in three of the past four quarters, with an average beat of 71.73%.
ZELTIQ AESTHETC Price and EPS Surprise
ZELTIQ AESTHETC Price and EPS Surprise | ZELTIQ AESTHETC Quote
Accelerate Diagnostics, Inc. (AXDX - Free Report)
This U.S.-based in vitro diagnostics company provides solutions for the diagnosis of serious infections. Accelerate Diagnostics is expected to report second-quarter 2016 earnings on Aug 8. We cannot predict an earnings beat for the company as it has an Earnings ESP of 0.00% and a Zacks Rank #4. We also note in the last reported quarter, the company registered an earnings miss of 11.54%.
ACCELERATE DIAG Price and EPS Surprise
ACCELERATE DIAG Price and EPS Surprise | ACCELERATE DIAG Quote
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>